Shares of Nuformix plc (LON:NFX – Get Free Report) were down 15.1% on Tuesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 9,097,313 shares changed hands during trading, a decline of 17% from the average daily volume of 10,972,615 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Stock Down 15.1 %
The stock has a 50 day simple moving average of GBX 0.05 and a 200-day simple moving average of GBX 0.13. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The firm has a market cap of £368,689.50, a PE ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- High Flyers: 3 Natural Gas Stocks for March 2022
- HCA Healthcare: 4 Reasons to Buy the 25% Dip
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Dividend Leaders Set for Strong Growth in 2025
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks to Gain From Stockpiling Effects of the Trump Tariffs
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
